Innovative Diagnostic Platform Akonni Biosystems has developed a revolutionary gel-drop microarray platform capable of multiplexed genetic testing at low costs, which positions them well to expand sales within global infectious disease diagnostics markets, particularly in regions with high MDR-TB prevalence.

Strong Funding & Recognition With recent awards including the North American New Product Innovation Award and significant grants from NIH, Akonni demonstrates validated innovation and financial backing, creating opportunities for partnerships, licensing, and large-scale deployments of their diagnostic solutions.

Market Expansion Potential Akonni's ongoing investments and grants reflect a focus on commercial readiness, enabling increased production capacity and market entry, particularly for complex infectious diseases, which can be targeted through strategic sales efforts to government health agencies and global health organizations.

Technological Edge Utilizing advanced platforms and cloud-based infrastructure, Akonni is positioned as a tech-forward company, offering a compelling value proposition to hospitals, labs, and healthcare providers seeking scalable, efficient, and cost-effective diagnostic solutions.

Collaborative Opportunities Given their active engagement with NIH and other research grants, there are substantial opportunities for collaboration with research institutions and public health sectors to co-develop and pilot new diagnostic tests, opening avenues for increased sales and product adoption.